BeiGene Says BRUKINSA Data At American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago Underscore Differentiated Clinical Profile For Treatment Of CLL And SLL
BeiGene Says BRUKINSA Data At American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago Underscore Differentiated Clinical Profile For Treatment Of CLL And SLL
The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton's tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
這些演講重點分析了BRUKINSA與其他用於治療慢性淋巴細胞白血病（CLL）和小淋巴細胞淋巴瘤（SLL）的布魯頓酪氨酸激酶抑制劑（BTKI）相比的療效和安全性。
"At this year's ASCO, multiple presentations continue to add to our extensive body of evidence demonstrating BRUKINSA's uniquely differentiated clinical profile," Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. "These new analyses, which highlight improved PFS and response rates and a low usage of antihypertensive medicines, provide valuable insights for oncologists to consider when making treatment decisions for their patients with CLL and SLL."
百濟神州血液學首席醫學官梅爾達德·莫巴舍爾醫學博士、M.P.H. M.P.H.：“在今年的ASCO上，多場演講繼續爲我們提供了大量證據，證明了BRUKINSA獨特的差異化臨床特徵。”“這些新分析突顯了PFS和反應率的提高以及降壓藥物的使用率較低，爲腫瘤學家在爲CLL和SLL患者做出治療決策時提供了寶貴的見解。”